Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ATHE with free AI briefings, catalyst countdowns, and dilution alerts.

ATHE · ALTERITY THERAPEUTICS LTD

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$37.3M Cash on Hand
19.9mo Cash Runway
Follow ATHE by email Get an email when ATHE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ATHE, unsubscribe in one click. Privacy

📣 What ATHE Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
ATH434 Multiple System Atrophy Phase 2 · NCT07729852 Enrolling by invitation
ATH434 dose level 1 Multiple System Atrophy Phase 2 · NCT05109091 Completed
ATH434 dose level 2 Multiple System Atrophy Phase 2 · NCT05109091 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ATHE holds $37.3M in cash and short-term investments and burns about $5.6M/quarter from operations, an estimated runway of 19.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 8 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ATHE files for a raise →

👥 Who Owns ATHE

Insiders 7.8% Institutions (24 holders) 2.1% Public and other holders 90.1%
HolderTypeShares% of sharesAs of
David Allen Stamler
Chief Executive Officer, Director
Insider 11,827,570 5.44% 2026-04-15
Lawrence Bernard Gozlan
Director · +1.00M options
Insider 4,545,455 2.09% 2026-04-10
Niven Abby Sarah Macnish
Chief Financial Officer
Insider 454,545 0.21% 2026-04-09
Peter Ashley Marks
Director
Insider 191,340 0.09% 2026-08-31

Share count 217,508,862 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ATHE picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ATHE and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.